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ttp://dx.doi.org/10.1016/j.ajpath.2014.11.018High-risk human papillomavirus (HPV) is a causative agent for an increasing subset of oropharyngeal
squamous cell carcinomas (OPSCCs), and current evidence supports these tumors as having identiﬁable risk
factors and improved response to therapy. However, the biochemical and molecular alterations underlying
the pathobiology of HPV-associated OPSCC (designated HPVþ OPSCC) remain unclear. Herein, we proﬁle
miRNA expression patterns in HPVþ OPSCC to provide a more detailed understanding of pathologic
molecular events and to identify biomarkers that may have applicability for early diagnosis, improved
staging, and prognostic stratiﬁcation. Differentially expressed miRNAs were identiﬁed in RNA isolated
from an initial clinical cohort of HPVþ/ OPSCC tumors by quantitative PCRebased miRNA proﬁling. This
oncogenic miRNA panel was validated using miRNA sequencing and clinical data from The Cancer Genome
Atlas and miRNA in situ hybridization. The HPV-associated oncogenic miRNA panel has potential utility in
diagnosis and disease stratiﬁcation and in mechanistic elucidation of molecular factors that contribute to
OPSCC development, progression, and differential response to therapy. (Am J Pathol 2015, 185: 679e692;
http://dx.doi.org/10.1016/j.ajpath.2014.11.018)Supported by NIH RL Kirschstein National Research Service Award F31
DE021926 (D.L.M.), NIH/National Cancer Institute research grant RO1
CA085870 (M.S.S.), and a Walther Cancer Foundation Advancing Basic
Cancer Research Grant (M.S.S.).
Disclosures: None declared.Head and neck squamous cell carcinoma (HNSCC) is a
leading cause of cancer death worldwide. High-risk human
papillomavirus (HPV), particularly HPV16, is a causative
agent for an increasing subset of oropharyngeal SCCs
(OPSCCs). Current evidence supports these tumors (desig-
nated HPVþ OPSCC) as having unique biology because they
have relatively low mutational density, wild-type cellular
tumor antigen p53, and p16 protein overexpression.1 HPVþ
OPSCC is already well established as a distinct clinical entity
with identiﬁable epidemiologic characteristics and risk fac-
tors.2 However, a detailed understanding of the biology and
the translation of that understanding into clinically applicable
tools to decrease mortality and to lessen morbidity from
treatment is clearly lacking. Although clinical trials assessing
differing management strategies for the two diseases arestigative Pathology.
.under way, currently, HPVþ patients are treated within the
standard of care guidelines for OPSCC, in the same
manner as HPV patients. However, HPVþ tumors of the
oropharynx are associated with distinct survival strata
because HPVþ patients have prolonged progression-free
responses and often, with appropriate surgical manage-
ment, chemotherapy, and irradiation, experience complete
responses that seem durable.3 Thus, early identiﬁcation
and characterization of this patient cohort is necessary to
tailor care to the unique biology of their tumors. As such,
Miller et alcharacterization of an HPV-driven OPSCC tumor is itself a
biomarker that demands management strategies distinct
from those associated with traditional HNSCC.
Owing to public health efforts regarding smoking cessation,
the overall incidence of most HNSCC has decreased in recent
years. In contrast, US incidence rates of OPSCC have
increased signiﬁcantly yearly between 1973 and 2004 for base
of tongue (1.3%) and tonsillar (0.6%) carcinomas, corre-
sponding to a 225% increase in the population-level incidence
of HPVþ OPSCC between 1984 and 2004.4,5 Among
individuals aged 12 to 69 years, oral HPV infection has an
overall prevalence of@w7%; however, men have a signiﬁ-
cantly higher prevalence compared with women (10.1%
versus 3.6%).6 These numbers are heavily inﬂuenced by
sexual behavior and smoking history: prevalence seems to be
as high as 20% in heavy smokers or individuals with >20
lifetime sexual partners. These trends are globally relevant
because OPSCC is increasing in several countries, particularly
in younger men.7 Furthermore, cervical cancer incidence is
declining in developed countries, whereas HPV-associated
orophargyneal cancers are projected to surpass annual
numbers of cervical cancers in the United States by 2020,
making HPVþ OPSCC the dominant HPV-associated cancer
in the United States.5 Therefore, prevention strategies for
HPVþ OPSCC are urgently needed, and developing clinically
useful biomarkers that are closely tied to the ability of the virus
to transform host cells and the subsequent neoplastic and
metastatic progressions are critical.
Expression proﬁling of cancers and functional studies per-
formed in cancer cell lines and murine models have revealed
provocative patterns implicating the importance of miRNA-
mRNA dysregulation in tumor development and progression.
Somewhat independent of miRNA biology, miRNA proﬁles
offer diagnostic and prognostic value in cancer and other dis-
eases that may guide treatment.8,9 Our aimwas to proﬁle HPVþ
versus HPVOPSCC to provide amore detailed understanding
of pathologic molecular events and to identify biomarkers that
may have applicability for early diagnosis, improved staging,
and prognostic stratiﬁcation. We identify an oncogenic miRNA
panel that represents the host response to an oncogenic HPV
infection and validate this panel in additional clinical cohorts
using publicly available sequencing and clinical data from The
Cancer Genome Atlas (TCGA; Bethesda, MD) and miRNA in
situ hybridization (ISH) analysis of arrayed human OPSCC
tissues. This molecular signature may help differentiate
oropharyngeal tumors with different prognoses and, thus,
distinct management strategies and facilitate mechanistic
elucidation of molecular factors that contribute to OPSCC
development, progression, and response to therapy.
Materials and Methods
Patient Samples for miRNA Proﬁling
Tissues for the initial study cohort were obtained from the
University of Missouri (Columbia, MO) surgical pathology680archives (2006 to 2011) with Institutional Review Board
approval and represent histologically conﬁrmed tonsillar or
base of tongue SCC (OPSCC). Tissue for study was iden-
tiﬁed by staining for p1610 according to the manufacturer’s
instructions (CINtec histology kit and E6H4 clone; Ventana
Medical Systems Inc., a member of the Roche Group,
Tucson, AZ) and was evaluated using a binary rating sys-
tem, with positive representing extensive (>50%) tumor
cellespeciﬁc cytoplasmic and nuclear staining. Negative
staining represented sparse or absent tumor-speciﬁc stain-
ing. Focal staining patterns, in the presence of mostly
negative staining, were interpreted as negative. All cases
included for laser capture microdissection represented
unambiguous staining patterns.
Laser Capture Microdissection
Using p16 staining, we identiﬁed cases from surgical exci-
sions that were strongly positive (>90% immunoreactivity
for p16 with minimal criteria 70%) or completely negative.
Of the 109 cases stained, 53 had sufﬁcient primary tumor
tissue available for laser capture, performed using the Arc-
turusXT system (Invitrogen, Carlsbad, CA). For each case, a
minimum of 8000 cancer cells were dissected, and caps were
stored at 80C. RNA puriﬁcation used the miRNeasy
formalin-ﬁxed, parafﬁn-embedded (FFPE) kit (Qiagen Inc.,
Valencia, CA). All the samples were assessed using a
NanoDrop spectrophotometer (Thermo Scientiﬁc, Wilming-
ton, DE) and Agilent 2100 bioanalyzer (Agilent Technologies
Inc., Santa Clara, CA). Additionally, a limited number of
samples were run on an miRNA QC PCR array (Qiagen Inc.)
as a means of positive control to assess the stability of the
small RNA fraction.
Real-Time PCR-Based miRNA Proﬁling
Qiagen’s miRNome global real-time quantitative PCR (qPCR)
array (Qiagen Inc.), which includes assays for 1008 individual
miRNA species, was used for proﬁling. Each array consisted
of three 384-well plates such that each patient’s sample was
run on three separate plates. The 1008 sequences proﬁled
represent all the annotatedmiRNA sequences (miRNAseqs) in
the human miRNA genome (miRBase release 16). cDNAwas
synthesized using the miScript II reverse transcription kit
(Qiagen Inc.), and qPCRwas performed using the LightCycler
480 system (Roche Applied Science, Indianapolis, IN). Each
assay was begun with hot start activation and included 45
cycles of ampliﬁcation and a melt curve analysis step for
determining the speciﬁcity of each probe (by calculating
melting temperature). Absolute quantitation was used to
generate threshold values using the second derivative
maximum algorithm unique to the LightCycler 480 system
(auto baseline). Statistical analysis was performed using the
geNorm algorithm. To improve the threshold of detection,
preampliﬁcation was performed on cDNA synthesized using
the miScript II reverse transcription kit using the miScriptajp.amjpathol.org - The American Journal of Pathology
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Figure 1 Human papillomavirus (HPV) prevalence in formalin-ﬁxed,
parafﬁn-embedded (FFPE) cases. A: The clinical history for patients diag-
nosed between 2006 to 2011 was reviewed, archived FFPE tissue blocks
were assessed for available tissue, and available hematoxylin and eosin
slides were reviewed. After an Institutional Review Boardeapproved
protocol, tissues were sectioned, stained for p16 protein expression, and
scored as positive or negative as described. The results showed that 58% of
cases were HPVþ as deﬁned in Materials and Methods. B: The average ages
in the p16þ and p16 cohorts under study were 56.49 and 61.00 years,
respectively. In the boxplot, the median is denoted by the solid horizontal
line within the rectangle. The top boundary is at 75th percentile and the
bottom boundary is at the 25th percentile. The whiskers extending from the
rectangle are set at 1.5 the interquartile range.
Oncogenic miRNAs in HPVþ Oral CarcinomaPreAMP PCR kit and miScript PreAMP primer mix (Qiagen
Inc.). Ampliﬁed cDNA was added to the miScript SYBR mix,
water, and miScript universal primer and was dispensed to
miRNome plates. A test miRNome array was ﬁrst used to
determine whether the dilution for real-time PCR resulted in a
high percentage of call rates. Preampliﬁed samples, including
p16þ (nZ 15) and p16 (nZ 9) samples, were loaded on the
miRNome plates (15 ng of cDNA per sample). Subsequent
analysis was performed as described above using CT 30 as a
cutoff point for inclusion.
FFPE-Based miRNA Cohort Bioinformatics
Raw data from the RT-PCR arrays were subjected to
extensive quality control analyses based on specialized
internal controls on the arrays including positive PCR
controls, which test the efﬁciency of the PCR itself, and
reverse transcription controls to detect any impurities that
inhibited the reverse transcription phase of the procedure.
We also calculated mean, SD, and coefﬁcient of variation
values and compared them with values published on FFPE
cancer samples for these arrays.11 Any sample that did not
fall within the acceptable range of metrics as deﬁned by
Qiagen Inc. was excluded from the analysis; one of the 24
samples failed this step. Next, miRNAs with CT values >30
(or 0) for preamplifed samples were considered not reliably
detected and were excluded from analysis by replacing that
CT with NA to indicate missing. Reference gene determi-
nation for normalization was performed on a plate-by-plate
basis according to the geNorm algorithm using the Bio-
conductor package SLqPCR version 1.26.0.12e16 To test
which miRNAs were differentially expressed based on HPV
status, we used the Bioconductor limma package version
3.16.7. To focus on widely expressed miRNAs and to in-
crease power, nonspeciﬁc ﬁltering of miRNAs was per-
formed as follows: only miRNAs that were detected in
>90% of samples were carried forward for subsequent
analysis. Moderated t statistics were applied to each miRNA
using an empirical Bayes approach in which the standard
errors are shrunk toward a common value.17 The comparison
of interest was HPVþ versus HPV, expressed in terms of
fold change (HPVþ/HPV). The comparison was made after
adjusting for smoking, smoking and HPV interaction, and
age to account for potential confounding effects. In the event
of a signiﬁcant interaction between smoking and HPV for a
speciﬁc miRNA, the interpretation of the effect of either
smoking or HPV in isolation was made with caution.
Validation of the Oncogenic miRNA Panel Using
Patient Cohorts from TCGA
Patient consent/enrollment and use of data were conducted in
accordance with TCGA Human Subjects Protection and Data
AccessPolicies.Clinical datawereﬁrst downloaded forHNSCC
patients (458 cases),HPV ISHorHPVp16 testingwas assessed,
and then patients with a deﬁnitive status (positive or negative)The American Journal of Pathology - ajp.amjpathol.orgwere selected, resulting in 66 cases. Of these, 11 cases were
positive and 11 were deﬁnitively HPVe according to p16
and/or HPV ISH. Annotated RNA sequencing data were
then downloaded from TCGA Data Portal in September and
October 2013. Because the comparison of interest was
HPVþ versus HPV cancer, individual normalized expres-
sion values for a particular miRNA were compared between
groups of HPVþ patients (nZ 11) and HPV patients (nZ
11) by using Student’s t-test, and the results were sorted
according to the level of signiﬁcance. For miRNAseq, the
relative abundance of a particular miRNA is represented by
the absolute number of sequence reads.Validation by miRNA ISH in HNSCC TMAs
HNSCC tissue microarrays (TMAs) were assembled from
cases available in the Department of Pathology and
Immunology, Washington University School of Medicine
(St. Louis, MO), using tissues obtained with approval of
the Human Research Protection Ofﬁce. The TMA included
357 cases of HNSCC, with two tumor tissue cores per case.
Immunohistochemical analysis was performed for p16 on a
full FFPE section using a Ventana BenchMark automated
immunostainer (Ventana Medical Systems Inc.) according
to standard protocols with a known p16-expressing SCC
case and normal tonsils as positive and negative controls,
respectively. Antigen retrieval used Ventana CC1, EDTA-
Tris, pH 8.0, solution. Staining was read by one study
pathologist (J.S.L.), and all the positive cases demonstrated
nuclear and cytoplasmic staining. Staining was graded in a
quartile manner as follows: 0 Z no staining, 1þZ 1% to
25% staining; 2þZ 26% to 50%; 3þZ 51% to 75%, and
4þZ 76% to 100%. Cases were then classiﬁed as positive681
Figure 2 Proﬁling of miRNA expression on
formalin-ﬁxed, parafﬁn-embedded samples by
quantitative RT-PCR. Tumors from 23 patients,
including 15 p16þ and eight p16 samples, were
proﬁled as described in Materials and Methods. A:
An unsupervised hierarchical clustering heat map
of normalized data (before nonspeciﬁc ﬁltering or
testing) representing 511 miRNAs is shown, with
red indicating greater levels of relative expression,
blue lesser levels, and white unreliable data
(CT > 30 or CTZ 0). The dendrogram at the top of
the heat map illustrates which patient samples had
the most similar miRNA proﬁles, whereas the
dendrogram on the left (y axis) illustrates which
miRNAs had similar proﬁles across patients. Items
that were most similar were linked sooner to each
other than items that were less similar. B: Clinical
information is shown for each sample, with a black
square marking the presence of the indicated
variable (gray indicates missing data); green [8 of
10 human papillomavirus (HPV) positive] and
salmon (6 of 13 HPV) shading indicate how the
samples cluster into two groups. Diff, differenti-
ated.
Miller et al(any convincing expression) versus negative, and then
separately as strong positive staining (3þ or 4þ) versus
negative or weak staining (0, 1þ, or 2þ). More than 90%
of cases were either strongly and diffusely positive or
completely negative. The TMAs were then processed for
RNA ISH for HPV or miRNA ISH for miR-9. ISH for high-
risk HPV E6/E7 RNA was performed using the RNAscope
HPV kit (Advanced Cell Diagnostics Inc., Hayward, CA)
according to the manufacturer’s instructions and was classi-
ﬁed by the study pathologist (J.S.L.) as either positive or
negative. Positive cases had granular cytoplasmic and/or
nuclear brown staining that was above the signal on the
negative control slide.
ISH for miR-9 was performed at the Center for RNA Inter-
ference and Non-Coding RNAs at MD Anderson Cancer
Center (Houston, TX). Double digoxigeninelabeled (50 and 30)
miRCURY LNA probes were obtained from Exiqon A/S
(Vedbaek, Denmark). For visualization, the digoxigenins were
detected with a polyclonal antidigoxigenin antibody and alka-
line phosphataseeconjugated secondary antibody using6825-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazo-
lium. In these experiments, the full-length mature miRNAseq
for miR-9 was used for speciﬁc LNA probes: 50-TCATA-
CAGCTAGATAACCAAAGA-30. All the tumor tissues
stained for miR-9 were counterstained with nuclear fast red.
One entire TMA was stained with LNA U6 snRNA probe as
positive controls without counterstain. Each TMA contained
normal reference tissues that served as orientation and as
negative controls (liver, thyroid, or small bowel). All the
resulting slides were assessed in a blinded manner (D.L.M.
and/or J.S.L.) as to HPV status, hematoxylin and eosin
morphology, and all other clinicopathologic parameters. The
stained slides were read and scored in a systematic manner
according to the following three parameters: i) proportion of
tumor cells with identiﬁable ISH signal (0 Z < 10%,
1Z 10% to 24%, 2Z 25% to 49%, 3Z 50% to 74%, and
4Z75%); ii) strength of ISH signal (weak, weak/moderate,
moderate, and strong); and iii) staining pattern (punctate,
diffuse, or punctate þ diffuse). The staining results were
tabulated and then unblinded and combined with dataajp.amjpathol.org - The American Journal of Pathology
Table 1 Oncogenic miRNA Proﬁle from FFPE HPVþ versus HPV
OPSCC Cases
miRNA
Fold
change Log2FC P value
hsa-miR-320a 2.83 1.5 2.02  103
hsa-miR-93-5p 2.36 1.24 5.41  103
hsa-miR-222-3p 2.31 1.21 4.58  103
hsa-miR-199a-3p//
hsa-miR-199b-3p
0.14 2.87 5.32  103
hsa-miR-199b-5p 0.14 2.85 8.80  103
hsa-miR-145-5p 0.20 2.30 5.91  103
hsa-miR-143-3p 0.21 2.28 2.50  103
hsa-miR-126-5p 0.23 2.14 5.48  103
hs-miR-126-3p 0.26 1.94 6.94  103
Fold change (FC) and log2FC are shown for the nine most statistically
signiﬁcant miRNA sequences, representing seven distinct miRNAs.
FFPE, formalin-ﬁxed, parafﬁn-embedded; HPV, human papillomavirus;
OPSCC, oropharyngeal squamous cell carcinoma.
Oncogenic miRNAs in HPVþ Oral Carcinomaregarding HPV status and additional clinical data. The sub-
sequent logistic regression analysis was performed separately
for each binary outcome (HPV status measured by p16 and
ISH), with the following for predictors: staining proportion,
strength of ISH signal, and staining pattern. Model selection
criteria were used to guide the selection of the ﬁnal variables
included in the model. Internal cross-validation was reported
to indicate the performance of the model.
Evaluation of E-Cadherin and miR-9 in Cell Lines
OPSCC cell lines of known HPV status, a gift from
Dr. Susanne M. Gollin (University of Pittsburgh, Pittsburgh,
PA), were cultured in M-10 medium containing L-glutamine,
gentamicin, and nonessential amino acids. For Western blot
analysis, 20 mg of protein from cell lysates was electro-
phoresed on SDS-PAGE and electroblotted to polyvinylidene
diﬂuoride membranes. Blots were probed with antieE-
cadherin primary antibody (BD #610181, clone 36 recog-
nizing the C-terminus, 1:100 dilution; BD Biosciences,
San Jose, CA) and a rabbit secondary antibody (Sigma
A-6667, 1:4000 dilution; Sigma-Aldrich, St. Louis, MO).
Loading controls were probed with rabbit polyclonal
antieglyceraldehyde-3-phosphate dehydrogenase (Abcam
#ab9485, 1:2000 dilution; Abcam Inc., Cambridge, MA) as a
primary antibody. To assess levels of miR-9 in cell lines,
RNA was extracted in technical triplicates using the miR-
CURY RNA isolation kit (Exiqon A/S) according to the
manufacturer’s instructions, polyadenylated, and reverse
transcribed into cDNA in a single reaction with the Universal
cDNA synthesis kit II (Exiqon A/S). A synthetic RNA spike-
in, UniSp6, was added to each sample to monitor reverse
transcription efﬁciency and reproducibility. The LNATM
primer sets for miR-9, four candidate reference genes, and
two positive control primer sets were obtained from Exiqon
A/S. cDNA from the reverse transcription reactions were
diluted 100 with nuclease-free water combined 1:1 with
2 PCR master mix (Exiqon A/S) and 0.05 ng of total RNA
per reaction. Real-time PCR ampliﬁcation and melting
curve analysis was performed using an ABI StepOnePlus
system (Applied Biosystems, Foster City, CA) in a stan-
dard (2-hour) run according to the following cycles: po-
lymerase activation/denaturation at 95C for 10 minutes,
ampliﬁcation for 40 cycles at 95C for 10 seconds, fol-
lowed by 60C for 1 minute at a ramp rate of 1.6 degrees
centigrade per second, and melting curve analysis as
speciﬁed by the StepOnePlus system.
Results
Characterization of Oropharyngeal Tissues
Because national and international rates of HPV-driven
OPSCC have been called epidemic in scale,18 we asked
whether patients previously diagnosed as having OPSCC at
the University of Missouri reﬂect concordant epidemiologicThe American Journal of Pathology - ajp.amjpathol.orgproportions. Of the cases (nZ 109) stained for p16 expres-
sion, 58% were positive (Figure 1A). Multi-institutional US
studies estimate that 65% to 70% of OPSCC is caused by
HPV.5 The average ages in the cohorts under study were
56.49 and 61.00 years for p16þ and p16, respectively
(Figure 1B and Supplemental Table S1). HPV/OPSCC has a
male predominance and no consistent association with
smoking. Disease staging also has been associated with dif-
ferences between HPVþ and HPV OPSCC, with HPVþ
disease more commonly associated with stage IV disease and
frequent lymph node metastases at initial presentation.
Overall, we interpret these clinical data as a positive signal
that the p16þ and p16 cohorts reﬂect true disease trends.
HPVþ and HPV Tumors Have Distinct miRNA Proﬁles
To identify a distinct miRNA signature that can differentiate
HPVþ from HPV OPSCC, we performed PCR-based
miRNA proﬁling using a minimum of ten 10-mm sections
from each of 24 cases. After preampliﬁcation, improved signal
detection was evident (Supplemental Figure S1). One case was
excluded based on quality control measures. Before nonspe-
ciﬁcﬁltering therewere 511miRNAs; afterward, 276miRNAs
remained and were used for modeling. Results from the linear
model showed that three individual miRNAseqs were signiﬁ-
cantlyup-regulated inHPVþ patients:miR-320a,miR-222-3p,
and miR-93-5p. The most statistically signiﬁcant down-
regulated miRNAs included six sequences representing four
unique mature miRNAs: miR-199a-3p//miR-199b-3p, miR-
143, miR-145, and miR-126a (Figure 2 and Table 1). The top
10 miRNAs that were most affected by age or smoking
status do not show fold changes of the magnitude we found
associatedwith HPV status (Supplemental Table S2). Three
miRNAs that showed a signiﬁcant HPV effect also had a
signiﬁcant smoking  HPV effect (miR-320a, miR-126,
and miR-143; results not shown). The full expression ma-
trix (511 miRNAs, 23 samples) was log2 transformed and
clustered using unsupervised hierarchical clustering based683
Figure 3 Unsupervised hierarchical clustering
heat map of miRNA expression in formalin-ﬁxed,
parafﬁn-embedded samples. A: An unsupervised
hierarchical clustering heat map of normalized
data representing 39 selected miRNAs is shown,
with red indicating greater levels of relative
expression, blue lesser levels, and white unreliable
data (CT > 30 or CT Z 0). The dendogram at the
top of the heat map illustrates which patient
samples had the most similar miRNA proﬁles,
whereas the dendrogram on the left (y axis)
illustrates which miRNAs had similar proﬁles across
patients. Items that were most similar were linked
sooner to each other than items that were less
similar. B: Clinical information is shown for each
sample, with a black square marking the presence
of the indicated variable (gray indicates missing
data); the samples sort into ﬁve distinct clusters,
with most samples falling into three groups: green
[mostly smokers regardless of human papilloma-
virus (HPV) status], salmon and blue (all HPVþ
nonsmokers), and pink and bright green (mixed).
Diff, differentiated.
Miller et alon average agglomeration with 1 rho as the distance
measure. The results are presented as a heat map, with
dendrograms indicating the clustering of patient samples
and miRNAs (Figure 2). Additional unsupervised hierar-
chical clustering was performed using a list of 39 miRNAs
implicated by the present data set and those from the liter-
ature (Figure 3). These analyses resulted in data that strongly
support the hypothesis that HPVþ oropharyngeal tumors
display distinct miRNA proﬁles and that groups of miRNAs
can be associated with an oncogenic HPV infection.
Correlation of miRNA Expression with HPV Expression
from TCGA Database Validates the PCR-Based
HPV-Associated miRNA Proﬁle
To further assess changes in the miRNA expression proﬁle
associated with HPVþ OPSCC, we used publically684available clinical and miRNAseq data from TCGA and
identiﬁed 11 primary OPSCC cases (tonsil or base of
tongue) positive for either p16 IHC or HPV ISH that were
paired with 11 HPV cases, which we designated as
TCGA cohort 1 (Supplemental Table S3). In TCGA cohort
1, we found 84 miRNAs to be signiﬁcant [P < 0.05 and
mean reads per kilobase of transcript per million reads
mapped (RPKM) >10 in both groups]. Using the average
RPKM for each group as general estimations of expression
level, fold changes were calculated and cutoff values of
log2 fold changes of 1.0 were used, yielding a list of 36
miRNAs (Supplemental Table S4).
The results from TCGA cohort 1 were compared with the
panel of miRNAs identiﬁed from the PCR proﬁling of FFPE
tissue. The fold changes of these seven miRNAs between
HPVþ and HPV patients are concordant between the
two data sets based on the Spearman rank correlationajp.amjpathol.org - The American Journal of Pathology
Figure 4 Analysis of The Cancer Genome Atlas (TCGA) cohort 1 miRNA
sequencing (miRNAseq) data. A: Patients composing TCGA cohort 1 were
identiﬁed as described. The graph shows comparison of the seven differ-
entially expressed miRNAs identiﬁed by PCR proﬁling of microdissected
formalin-ﬁxed, parafﬁn-embedded (fold changes in log2 scale for symme-
try) versus results obtained from analysis of TCGA cohort 1 miRNAseq data.
Strong concordance between the data sets was obtained based on the
Spearman rank correlation (rho Z 0.85; P Z 0.02) and the Pearson
product moment correlation (r Z 0.83; P Z 0.02; 95% CI, 0.21e0.97). A
best-ﬁt line (solid) indicated this relative concordance, whereas a 45
reference line (dashed) indicated that there was not perfect absolute
agreement between the data sets and the assay technique. B: Mean
normalized miRNA read counts showing miR-199-1 as a validated human
papillomavirus (HPV)eassociated miRNA. C: Mean normalized miRNA read
counts showed up-regulation of miR-106b in HPVþ tumors. D: Mean
normalized read counts showed that miR-9 was signiﬁcantly up-regulated
in HPVþ tumors. All the error bars indicate 95% CIs. *P < 0.05. qPCR,
real-time quantitative PCR.
Oncogenic miRNAs in HPVþ Oral Carcinoma(rho Z 0.85; P Z 0.02) and the Pearson correlation
(r Z 0.83; P Z 0.02; 95% CI, 0.21e0.97) (Figure 4A).
Among the most statistically signiﬁcant miRNAs from
TCGA cohort 1, 16 of which are shown in Table 2, miR-
199-1, miR-106b, and miR-9 were highly correlated to pa-
tients who are HPVþ irrespective of other covariates, such
as age or smoking status (Figure 4, BeD). miR-9 was up-
regulated 1.84-fold (P Z 0.14) in the FFPE qPCR cohort,
and it has been identiﬁed by two independent published
studies as an HPV-associated miRNA in OPSCC. There-
fore, the up-regulation of miR-9-1 and miR-9-2 in TCGA
cohort 1 miRNAseq data served as strong validation that
this is an HPV-associated miRNA in OPSCC. Unsupervised
clustering performed on the full miRNAseq data indicated
that, in this data set, HPVþ disease is associated with
distinct miRNA proﬁles (Figure 5). Notably, a group of
miRNAs that are highly expressed in HPVþ and HPV
disease, including miR-21, miR-203, and miR-22, clustered
at the bottom of this heat map, implicating these miRNAsThe American Journal of Pathology - ajp.amjpathol.orgas potentially important in squamous differentiation of
HNSCC regardless of HPV status.
Further Validation Studies Using TCGA and miRNA ISH
Based on a recent analysis of mRNAseq data from TCGA
across 3775 malignancies for the presence of viral se-
quences, a second expanded cohort of patients from TCGA
with HPV-associated HNSCC was identiﬁed19 that
comprised 20 cases that lacked available clinical data
regarding p16 or HPV ISH and were, therefore, not identiﬁed
in the original analyses. However, these 20 cases were shown
to express various viral transcripts (18 cases expressed tran-
scripts from HPV16 and two from HPV33) and to have HPV
DNA integrated into the host genome and were, thus, treated
as HPVþ and were compared with an additional set of 29
HPV cases (identiﬁed based on available p16 and/or HPV
ISH data), herein designated TCGA cohort 2 (Supplemental
Table S5). After extracting miRNAs that were expressed at
suitable levels in both cohorts (>10 mean RPKM), a list of
43 miRNAs was generated (Supplemental Table S4), the top
10 of which are shown in Table 2. The fold changes of the
seven-miRNA panel from FFPE studies show concordance
between the two data sets based on the Spearman rank cor-
relation (rhoZ 0.75; PZ 0.06) and the Pearson correlation
(rZ 0.78; PZ 0.03) (Figure 6). miR-9 and miR-106b were
again among the most statistically signiﬁcant miRNAs. miR-
9-1 and miR-9-2 were expressed at RPKM of approximately
5000 in patients whose tumors express HPV transcripts. This
is in stark contrast to patients whose tumors were negative
for p16 IHC and/or HPV ISH, where, on average, miR-9
levels were approximately 16-fold lower. The tissue level
of miR-9 expression was also assessed via ISH on HNSCC
TMAs containing 357 cases, including 270 OPSCC cases
with known p16 status and 226 cases with known HPV
RNA ISH results. Representative positive and negative
punctate and diffuse staining is shown in Figure 7. The
odds that high-tumor miR-9 expression occurs in the
setting of p16þ disease were more than three times greater
[odds ratio (OR) Z 3.38; P < 0.001; 95% CI, 1.84e6.26]
than the odds of low-tumor miR-9 expression; similarly,
the odds of diffuse miR-9 ISH were nearly four times
greater (ORZ 3.87; P < 0.001; 95% CI, 2.10e7.20) than
the odds of nondiffuse miR-9 ISH (Figure 8). When the
OR calculations were based on HPV mRNA ISH, the ORs
increased (ORZ 4.41; P < 0.001; 95% CI, 2.30e8.51 and
OR Z 5.76; P < 0.001; 95% CI, 2.99e11.36) for both
miR-9 positivity and a diffuse cytoplasmic/nuclear pattern
for miR-9 ISH signal (Figure 8). As has been shown in
analyses of FFPE samples and analysis of TCGA cohort 1
(p16/ISH-conﬁrmed cases), HPV-associated tumors are
characterized by up-regulation of miRNAs belonging to
the miR-106bw25 cluster (miR-106b, miR-93, miR-25).
The validation studies using TCGA cohort 2 strongly
support up-regulation of members of this cluster in
association with HPV status. Furthermore, the expression685
Table 2 Analysis of TCGA Cohorts 1 and 2
Data source miRNA
Mean RPKM
Fold change Log2FC P valueHPV
þ HPV
TCGA cohort 1 hsa-miR-106b 1225 542 2.26 1.18 1.7  105
hsa-miR-148a 54,501 20,645 2.64 1.40 4.8  105
hsa-miR-625 306 111 2.76 1.46 8.8  105
hsa-miR-335 113 41 2.71 1.44 5.4  104
hsa-miR-9-1 5078 1054 4.81 2.27 5.4  104
hsa-miR-9-2 5091 1055 4.82 2.27 5.8  104
hsa-miR-214 13 46 0.30 1.75 8.9  104
hsa-miR-337 10 36 0.29 1.79 1.3  103
hsa-miR-378c 24 7 3.49 1.80 1.7  103
hsa-miR-29c 4456 1204 3.70 1.89 2.5  103
hsa-miR-598 38 14 2.68 1.42 3.3  103
hsa-miR-107 133 52 2.55 1.35 5.2  103
hsa-miR-150 2796 746 3.75 1.91 5.6  103
hsa-miR-106a 55 18 3.05 1.61 6.6  103
hsa-miR-378 2154 742 2.90 1.54 6.7  103
hsa-miR-20b 152 9 16.61 4.05 7.4  103
TCGA cohort 2 hsa-miR-20b 47 7 6.79 2.76 2.6  104
hsa-miR-9-2 5287 325 16.26 4.02 5.4  104
hsa-miR-9-1 5282 326 16.18 4.02 5.4  104
hsa-miR-106b 990 587 1.69 0.75 5.4  104
hsa-miR-574 44 69 0.63 0.66 6.8  104
hsa-miR-193b 101 256 0.40 1.34 9.0  104
hsa-miR-363 30 7 4.38 2.13 9.3  104
hsa-miR-16-2 23 11 1.99 0.99 1.7  103
hsa-miR-15b 521 269 1.93 0.95 1.7  103
hsa-miR-25 11,787 7377 1.60 0.68 1.8  103
Fold change (FC) and log2FC are shown for the most statistically signiﬁcant miRNA sequences from each cohort.
HPV, human papillomavirus; RPKM, reads per kilobase of transcript per million reads mapped; TCGA, The Cancer Genome Atlas.
Miller et allevels of the closely related miR-106aw363 cluster (miR-
20b and miR-363) are tightly correlated with HPV status,
although the expression levels of these miRNAs are low,
making it difﬁcult to interpret the potential biological
signiﬁcance (Table 2). Note that others have reported up-
regulation of miR-20b and miR-363 based on qPCR
proﬁling and microarray analyses of FFPE samples and
cell lines, respectively (Supplemental Table S6).20,21
Discussion
HPV-Associated miRNA Proﬁling
The incidence rates for HPVþ OPSCC increased dramati-
cally from 1988 to 2004, from 0.8 to 2.6 per 100,000, an
increase of 225%.5 In striking contrast, HPV-negative can-
cers have declined 50%. These trends are also apparent
internationally.7 Thus, it is of great interest to identify
speciﬁc up-regulated miRNAs characteristic of an onco-
genic HPV infection of the head and neck, as these miRNAs
may represent novel diagnostic/prognostic biomarkers and
may provide a more detailed understanding of the molecular
pathogenesis of the disease. We provided miRNA proﬁles
of three independent cohorts of patients (nZ 94) with SCC
of the aerodigestive tract performed with PCR arrays and686next-generation deep sequencing. Comparative analysis of
these cohorts strongly supports HPV-associated up-regula-
tion of miR-9 and members of the miR-106bw25 cluster
and down-regulation of miR-199-1.
The fundamental mechanism associated with HPVþ dis-
ease is a disruption of cellular differentiation induced by the
virus, wherein the cell acquires resistance to growth inhi-
bition, immune evasion, subversion of apoptosis, genomic
instability, and, ultimately, dysregulated proliferation such
that viral DNA can replicate in synchrony with chromo-
somal DNA. Thus, HPV may causally modulate miRNAs
that then act as central nodes in affecting numerous genes
important in progression and metastatic spread, resulting in
divergent gene regulation. In contrast to cervical cancer,
viral integration is not necessary for the initiation of onco-
genesis in OPSCC, and episomal HPV DNA seems to be a
frequent occurrence in tonsillar carcinomas.22 However,
similar to cervical cancer, transcriptionally active HPV is
linked to the differentiation state of the host cell and in some
circumstances leads to aberrant cell proliferation and
genomic instability that is due, in part, to mitotic spindle
defects that result in cytogenetic abnormalities.23 Alterna-
tively, miRNAs could be suppressed owing to aberrant
DNA methylation or chromosomal disruption.24 Because an
individual miRNA can affect hundreds to thousands ofajp.amjpathol.org - The American Journal of Pathology
Figure 5 Heat map of normalized expression
data from The Cancer Genome Atlas (TCGA)
cohort 1. The color scale represents greater (red)
or lesser (blue) levels of relative expression across
TCGA head and neck squamous cell carcinoma
samples (columns) and miRNAs (rows). Unsuper-
vised hierarchical clustering of the samples and
the miRNAs was performed using Euclidean dis-
tance and the average linkage methods, and the
resulting dendrograms are shown in the margins,
where þ or  indicates human papillomavirus
(HPV) status. Items that are most similar cluster
lower in the dendrogram. There seem to be two
distinct clusters of samples, one entirely HPVþ and
the other mostly HPV, as well as four distinct
clusters of miRNAs. As an example, reﬂecting the
color scale, the bottom rows show miRNA
expressed across all samples at levels of 15,000 to
320,000 reads per million miRNA mapped
(Supplemental Table S4).
Oncogenic miRNAs in HPVþ Oral Carcinomagenes, many of these often lie in the same biological
pathway.25 Thus, speciﬁc cellular pathways important for
immune surveillance, mitogenic signaling, or metabolism,
which are integral for HPV infection, could also lead to
typiﬁed miRNA expression.
Several studies have examined miRNA expression in the
context of HPV and head and neck cancer, with heretofore a
lack of consensus among reports.20,21,26e28 This may be
due, in part, to the biological redundancy in miRNA func-
tion, the inherent genomic instability characteristic of HPVþ
tumors, and the use of differing proﬁling methods and
sample sizes. Nevertheless, emerging common themes
among the various data sets are shown in Supplemental
Table S6, which summarizes miRNAs identiﬁed in at least
two independent studies. Note that miR-20b shares signiﬁ-
cant sequence homology with miR-106b and miR-93, these
miRNAs share the same seed sequence, and they are closely
related to miR-363. It has been reported that members of the
miR-106bw25 cluster are up-regulated independent of HPVThe American Journal of Pathology - ajp.amjpathol.orgstatus relative to normal tonsillar epithelium (nZ 88 versus
n Z 7).21 This is in contrast to the present study showing
up-regulation of members of the miR-106bw25 cluster in
HPVþ OPSCC relative to HPV as determined in the FFPE
PCR-based miRNA proﬁle, TCGA cohort 1, and TCGA cohort
2. Recent in vitro experiments that sought to identify miRNAs
altered as a function of HPV transfection used deep
sequencing on organotypic raft cultures derived from normal
or HPV31-transfected human foreskin keratinocytes isolated
from the same donor, demonstrating two- to three-fold
up-regulation of miR-106b and miR-25 in the HPV-
transfected cultures relative to normal.29 In the context of the
current human tumor data, this study strongly supports that
these miRNAs are altered as a function of HPV oncoproteins.
TCGA deep sequencing data sets analyzed herein add
another dimension to available data on the expression of
miRNAs shown to be statistically signiﬁcant between HPVþ
and HPV disease, as normalized read counts provide in-
formation on the relative abundance of a speciﬁc miRNA.687
Figure 6 Analysis of The Cancer Genome Atlas (TCGA) cohort 2 miRNA
sequencing (miRNAseq) data. A: Patients in TCGA cohort 2 were identiﬁed
as described in Materials and Methods. The graph shows comparison of the
seven differentially expressed miRNAs identiﬁed by PCR proﬁling of
microdissected formalin-ﬁxed, parafﬁn-embedded (fold changes in log2
scale) versus results obtained from analysis of TCGA cohort 2 miRNAseq
data. A strong concordance between data sets was obtained based on the
Spearman rank correlation (rho Z 0.75; P Z 0.06) and the Pearson
product moment correlation (r Z 0.78; P Z 0.03; 95% CI, 0.07e0.96). A
best-ﬁt line (solid) indicates this relative concordance, whereas a 45
reference line (dashed) indicates that there is not perfect absolute
agreement between the data sets and the assay technique. B: Mean
normalized miRNA read counts showing miR-106b as a validated human
papillomavirus (HPV)eassociated miRNA. C: Mean normalized miRNA read
counts showing miR-9 as a validated HPV-associated miRNA. All the error
bars indicate 95% CIs. *P < 0.05. qPCR, real-time quantitative PCR.
Miller et alThus, it is interesting to note that miR-363, which has been
shown to be up-regulated via microarray analysis in HPVþ
disease by two independent studies, shows relatively low
expression overall (<50 RPM in HPVþ and HPV cohorts),
yet the fold change for this miRNA is quite high. Similar in
this regard is miR-20b, part of the same transcriptional unit
and also previously reported21 as up-regulated in HPVþ
disease. In the present study, we observed up-regulation of
miR-20b (16- and 7-fold in TCGA cohorts 1 and 2,
respectively); however, it is also expressed at relatively low
levels. In contrast, miR-106b and members of the miR-
106bw25 cluster are expressed at levels approximately 30-
fold higher. Because the biological signiﬁcance of these
fold differences are unknown, the relative importance of the
two clusters in HPVþ OPSCC should be addressed experi-
mentally because it is unclear whether expression of these688miRNAs at very low levels may nevertheless regulate
important biological functions.
Up-Regulated miRNAs
miRNA families are determined based on common seed
sequence and are predicted to target overlapping sets of
genes. miR-106bw25 and miR-106aw363 are genomic
paralogs of the miR-17w92 cluster, one of the best-
characterized groups of miRNAs in human cancer, with
oncogenic function in lymphoma, multiple myeloma,
medulloblastoma, lung cancer, and colorectal cancer.30,31
miR-106b, miR-93, and miR-20b are members of the miR-
17 family; as such, their seed sequence AAAGUG is iden-
tical to that of miR-17, miR-20a, miR-20b, miR-106a, and
miR-106b, and they are predicted to have redundant func-
tion.32 However, the biological implications of intracluster
redundancy are not entirely understood, as clustering of
microRNAs with similar seed sequences is highly conserved,
which suggests that members of the same cluster with iden-
tical seed sequences may have functional importance.
Members of the miR-106bw25 and/or miR-106aw363
cluster seem to be sensitive for differentiating HPVþ from
HPV HNSCC; however, the mechanistic basis for up-
regulation is not entirely clear. HPVþ HNSCC and cervi-
cal cancers are characterized by up-regulated expression of
distinct and larger subsets of cell cycle and DNA replication
genes,33,34 and transcription of miR-106bw25 is concurrent
with the protein coding gene MCM7.31 Indeed, MCM7 is a
known RB/E2F target gene, and E2F family transcription
factors may be paramount in mediating miR-106bw25 and
MCM7 transcription.35 The MCM7 promoter has RB/E2F
binding sites, and mRNA expression correlates with miR-
106b expression.36 This is provocative because MCM7
has been proposed as a protein biomarker that distinguishes
between HPVþ and HPV HNSCC.37 Thus, the miR-
106bw25 cluster members may be sensitive for differenti-
ating HPVþ from HPV HNSCC as relatively increased
expression of this cluster is highly characteristic of HPVþ
tumors.
There is also considerable evidence that miR-106bw25
and its paralogs can act as bona ﬁde oncogenes (oncomirs)
with deﬁned roles in overcoming transforming growth
factor bemediated growth suppression, enhancing trans-
forming growth factor b signaling, cell-cycle promotion,
and increased cell survival.38 Repression of MCM7
together with miR-106bw25 expression is associated with
induction of p21 and phosphatase and tensin homolog in
breast and prostate cancer.35 In neuroblastoma, miR-
17w92 expression induced potent inhibition of key trans-
forming growth factor b signaling effectors and direct in-
hibition of transforming growth factor beresponsive
genes.39 Increased expression of miR-106bw25 and miR-
17w92 in retinoblastoma was also reported,40 leading to
the hypothesis that in the context of genetic Rb loss, high
miR-17w92 expression may circumvent the need for theajp.amjpathol.org - The American Journal of Pathology
Figure 7 In situ hybridization (ISH) analysis of miR-9 expression in
head and neck squamous cell carcinoma. AeD: Low-power images depicting
ISH patterns for miR-9 in four oropharyngeal squamous cell carcinoma
tissue cores. The ISH signal is represented by a deep purple color. The
counterstain for miRNA-probed tissues sections was nuclear fast red;
therefore, purple coloration represents ISH signal and pink/red is the
counterstain. A and C: Human papillomavirus (HPV)epositive tumors
showed a strong ISH signal. B and D: HPV tumors had a weak or absent
ISH signal. EeH: High-power images depicting ISH patterns for miR-9 in
four oropharyngeal squamous cell carcinoma tissue cores. Staining in HPVþ
cores was punctate (E) or diffuse (G), whereas HPVe tumors had weak or
absent signal. IeL: Corresponding hematoxylin and eosin images. Original
magniﬁcation: 100 (AeD); 400 (EeL).
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The American Journal of Pathology - ajp.amjpathol.orglarge numbers of genetic hits required for tumorigenesis.
These results highlight the importance of context in
miRNA oncogenic function and suggest the hypothesis
that the current ﬁnding of miR-93, miR-106b, miR-20b,
and miR-363 overexpression in OPSCC tumors supports
the oncogenic activity instigated by the main viral onco-
proteins: E6, E7, and E5.
In addition to the miR106bw25 cluster, strong up-
regulation of miR-9 is also observed in HPVþ OPSCC.
miR-9 has been linked to metastatic potential via modula-
tion of E-cadherin, acting to prime breast cancer cells for an
epithelial-mesenchymal transition and stimulate angiogen-
esis.41 Because lymph node metastasis is extremely com-
mon in patients with HPVþ OPSCC, and increased miR-9
levels in HPVþ relative to HPV OPSCC were observed
in the present study and others,21,27 we asked whether there
was a relationship between miR-9 and E-cadherin expres-
sion in OPSCC using RT-qPCR and Western blot analysis
of OPSCC cell lines of known HPV status (Supplemental
Figure S2); however, no relationship between miR-9 and
E-cadherin was observed. Expression of E-cadherin is
generally inversely correlated with prognosis in HNSCC,
with early studies showing reduced E-cadherin expression
as an independent prognostic marker for metastasis and
local recurrence.42 A recent study (n Z 152) reported that
the expression of E-cadherin is extensive in OPSCC, with
no correlation between E-cadherin and HPV, nodal or
distant metastasis, histopathologic type, or survival.43 A
second analysis (n Z 102) suggested that HPVþ/p16þ tu-
mors from the oropharynx express high E-cadherin and b-
catenin levels.44 Together, these results indicate that high
miR-9 in HPVþ OPSCC is not directly altering E-cadherin
expression, suggesting that other functionally important
miR-9 targets should be explored. Interestingly, miR-9 may
modulate the microenvironment in HPVþ OPSCC, as there
is compelling evidence that miR-9 is packaged into
microvesicles or may function as a tumor suppressor.45,46
Physiologic miR-9 expression may temper innate immune
responses.47 In cancer, there is limited evidence that miR-9
may be involved in modulating immunoregulatory genes,
including major histocompatibility complex class Ie and
interferon-regulated genes.48 Data surrounding miR-9 and
adaptive immune response are also lacking. Nonetheless,
the biology associated with adaptive immune response in
HPVþ OPSCC is of particular interest and clinically rele-
vant as these tumors are being considered for immune
checkpoint inhibitor therapy with antieprogrammed cell
death 1 or programmed cell death ligand 1 antibodies and
adoptive cell transfer therapy.49 It has also been shown that
most transcriptionally active HPVþ OPSCC tumors express
programmed cell death ligand 1 (also called B7-H1),
although the signiﬁcance of this and its relevance to patient
survival may be limited.49,50 Thus, in light of strong up-
regulation of miR-9 in HPVþ OPSCC, future studies will
correlate miR-9 expression and the presence of immune
inﬁltrates.689
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Figure 8 Odds ratios (ORs) and mosaic plots of high-tumor miR-9 occurring in relation to p16 status. AeC: The odds that high-tumor miR-9 expression
occurs in the setting of p16þ disease were more than three times greater (OR Z 3.38; P < 0.001; 95% CI, 1.84e6.26) than the odds of low-tumor miR-9
expression in p16þ; similarly, the odds of diffuse miR-9 in situ hybridization (ISH) were nearly four times greater in p16þ (OR Z 3.87; P < 0.001; 95% CI,
2.10e7.20) than the odds of nondiffuse miR-9 ISH in p16þ. DeF: The ORs increased when the outcome was validated human papillomavirus (HPV) mRNA ISH.
The model prediction based on HPV mRNA ISH had sensitivity Z 0.62 and speciﬁcity Z 0.875.
Miller et alDown-Regulated miRNAs
Down-regulation of miR-143, miR-145, miR-199a-3p, miR-
199b-3p, miR-199b-5p, and miR-126 has been observed in
HPVþ OPSCC and cervical disease.26,28 Similar results
were obtained in an organotypic keratinocyte raft culture
model, showing signiﬁcant down-regulation of miR-199a-
5p and miR-145, suggesting a potential mechanistic link
to early stages of the HPV life cycle.29 The present analyses
on nonpreampliﬁed patient samples offered preliminary
suggestions that miR-199 and miR-145 were also down-
regulated in patient samples (data not shown). After
analyzing ampliﬁed samples and calculating relative
expression of miRNAs based on the geNorm algorithm, an
extremely robust and informatics-intensive method for
analyzing RT-qPCR data, the data set conﬁdently supports
an HPV-speciﬁc down-regulation of miR-145. The seed
sequence of miR-145 is present in the E1 open reading
frame of a variety of papillomaviruses, and E1 has been
shown to be a bona ﬁde miR-145ereactive element.29
Moreover, miR-145 plays a role in modulating the viral
life cycle, with a differentiation-dependent reduction in
levels of this miRNA in HPV-transfected compared with
control keratinocyte raft cultures that seems to depend
on the function of viral E7 protein. Lentiviral forced
expression of miR-145 plays a role in controlling genome
ampliﬁcation with a signiﬁcant reduction of episomal viral
DNA in undifferentiated cells. These in vitro data should be690interpreted as having true biological signiﬁcance because
other studies evaluating miRNA proﬁles in HNSCC and
cervical cancer corroborate an HPV-associated down-regu-
lation of miR-145 and miR-143.26 Taken together, these data
indicate that HPV may down-regulate miR-145 to allow for
differentiation-speciﬁc genome ampliﬁcation and that this
miRNA remains repressed in human tumors. In this context,
we can understand miR-145 as a putative tumor-suppressive
miRNA in HPV disease.Conclusions
Most HPVþ HNSCC tumors arise deep in the crypts of the
tonsils of the oropharynx. These tumors are often obscured
from routine gross visualization in dental examinations and,
as such, most patients present with lymph node metastases.
However, relative to patients with HPV OPSCC, HPVþ
status is positively correlated with a two- to three-fold
increase in overall survival,3 indicating that the time is
rapidly approaching whereupon HPV status will dictate
therapy. The HPV-associated oncogenic miRNA panel
identiﬁed herein may be incorporated into a multitarget
diagnostic platform that can contribute to early detection
and/or disease stratiﬁcation to aid in differentiating oropha-
ryngeal tumors with different prognoses and, thus, distinct
management strategies. Furthermore, the oncogenic miRNA
panel will facilitate the mechanistic elucidation of molecularajp.amjpathol.org - The American Journal of Pathology
Oncogenic miRNAs in HPVþ Oral Carcinomafactors that contribute to OPSCC development, progression,
and response to therapy.
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